Health and Human Services Secretary Robert F. Kennedy Jr. announced on Wednesday that the federal government will allow widespread patient access to unapproved peptide injections that have gained popularity through internet influencers, drawing sharp warnings from drug safety experts. The unilateral move implements an “enforcement discretion” policy, allowing companies to produce and distribute unproven compounds without undergoing standard Food and Drug Administration review processes. These traditional safeguards include clinical trials to test whether substances outperform placebos and evaluations for potential risks such as cancer or birth defects.
The policy document released Wednesday stated that Mr. Kennedy determined the action “advances patient choice and freedom while appropriately protecting patient safety.” However, the decision bypassed standard agency protocol; F.D.A. scientists had previously advised against the widespread use of these peptides, and agency experts were absent from at least one meeting held Tuesday to finalize the policy.
Emily Hilliard, a spokeswoman for the Department of Health and Human Services, defended the framework by stating it aims to confront the risks of black-market peptides. She noted that the policy requires patient-specific prescriptions, traceable ingredients, quality testing, and mandatory adverse event reporting to hold compounders accountable. Crucially, Hilliard added, “The policy does not grant F.D.A. approval or establish clinical safety and effectiveness.”
Peptides are short chains of amino acids that deliver basic instructions to the body. While certain peptide compounds such as insulin for diabetes and GLP-1 weight-loss medications are F.D.A.-approved, the newly permitted substances lack the costly, regulated studies required by major pharmaceutical companies. The six compounds now permitted under the policy include epitalon, marketed for longevity, and BPC-157, often called the “wolverine” peptide and purported to aid muscle repair and joint healing. Other included substances are semax, promoted for mental health and neurological conditions like anxiety and Parkinson’s disease; KPV, used for wound healing and inflammatory skin conditions; MOTS-c, suggested to affect cellular metabolism without human data support; and TB-500, a substance originally developed as a veterinary drug to enhance greyhound and horse racing performance.
Experts noted that some of these compounds target fundamental biological processes, creating potential health risks. Epitalon, for instance, is promoted for its reported ability to lengthen telomeres—chromosomal caps that shorten with age. However, researchers have linked longer telomeres to cancer, raising concerns that the compound could be carcinogenic. Critics fear that patients may substitute these unproven therapies for established medications with verified safety and efficacy tracks.
The policy shift aligns with the “medical freedom” movement supported by Mr. Kennedy and his base, which frequently favors alternative treatments over heavily studied vaccines and pharmaceuticals. Mr. Kennedy himself has stated publicly that he has benefited from using peptides and championed their wider availability on podcasts earlier this year.
To address safety concerns, the new framework includes specific criteria for manufacturers. Peptides must be produced in F.D.A.-registered facilities—a designation that primarily requires companies to register their addresses with the agency—and products must feature labels listing active ingredients, strength, and a unique facility identifier. Telehealth companies and compounding pharmacies, including firms like Hims & Hers and Noom, have expressed interest in dispensing the compounds.
The regulatory pathway leading to this decision involved a compounding committee meeting in July to consider adding seven peptides to a list of substances bespoke pharmacies can compound for individual patients. During those hearings, F.D.A. officials and safety advocates warned about a lack of basic data regarding immune system effects and tumor growth risks. Agency scientists formally advised the committee against adding the peptides. Conversely, other witnesses testified about personal benefits and general drug risks. The committee, which had been populated by Mr. Kennedy’s department with members who prescribed peptides or worked in compounding, ultimately voted to recommend the compounds, though the agency did not immediately enact the list.
Dr. Janet Woodcock, who retired from the F.D.A. in 2024 after four decades of drug oversight, criticized the new direction. She said the policy of enforcement discretion “is just a policy of looking the other way” and harks back to unregulated folk medicine. She noted that bypassing pre-market testing undermines the regulatory safeguards originally established to prevent disasters like the distribution of thalidomide.
John Hertig, chairman of the Collaborative for Evidence-Based Medicines, voiced concern over how consumers might interpret the directive. He suggested the policy could be viewed by the public as a tacit federal endorsement, noting it lacks the rigorous scientific diligence and review that Americans deserve for products they ingest or inject.
